Severe Adverse Events Biomarkers Investigation on Extensive Stage Small Cell Lung Cancer
Sponsor
Hunan Province Tumor Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05055908
Collaborator
(none)
60
1
29.5
2
Study Details
Study Description
Brief Summary
The purpose of the trial is to find some biomarkers to predict the the severe adverse events of Atezolizumab plus etoposide and platinum based chemotherapy as the first line treatment in extensive stage small cell lung cancer. Mainly observe the patient's abnormal symptoms after treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
60 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Severe Adverse Events Biomarkers Investigation on Extensive Stage Small Cell Lung Cancer Who Treated With Atezolizumab Plus Etoposide and Platinum Based Chemotherapy
Actual Study Start Date
:
Apr 1, 2019
Actual Primary Completion Date
:
Jul 1, 2021
Actual Study Completion Date
:
Sep 14, 2021
Outcome Measures
Primary Outcome Measures
- PFS [April 2019- July 2021]
Progression free survival
- OS [April 2019- July 2021]
Overall survival
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- 18， Extensive Stage Small Cell Lung Cancer Confirmed by Histopathology Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy
Exclusion Criteria:
- Patients with contraindication of chemotherapy Pregnant or breast feeding women
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hunan Cancer Hospital | Changsha | Hunan | China | 410013 |
Sponsors and Collaborators
- Hunan Province Tumor Hospital
Investigators
- Principal Investigator: Yongchang Zhang, MD, Hunan Cancer Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Yongchang Zhang,
Director, Head of Medical Oncology, Principal Investigator, Clinical Professor,
Hunan Province Tumor Hospital
ClinicalTrials.gov Identifier:
NCT05055908
Other Study ID Numbers:
- ESCAPE
First Posted:
Sep 24, 2021
Last Update Posted:
Jan 25, 2022
Last Verified:
Apr 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: